GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2012

Mallinckrodt Buys CNS Therapeutics for $100M

  • Mallinckrodt is buying CNS Therapeutics for about $100 million. The acquired firm is focused on the development and commercialization of pharmaceuticals for site-specific delivery to the central nervous system, for the treatment of neurological disorders and intractable cancer pain. Its FDA-approved product, Gablofen® (baclofen injection) is a branded AP-rated generic Lioresal® Intrathecal (baclofen injection) for the treatment of spasticity.

    “This acquisition supports our strategy of leveraging our therapeutic expertise and our core capabilities in manufacturing, regulatory, and commercialization to serve patients,” comments Mark Trudeau, Mallinckrodt president for pharmaceuticals. “CNS Therapeutics' marketed product line complements our branded portfolio. Their central nervous system and pain management products in development complement our pipeline and address an important need for patients.”

    Mallinckrodt is the pharmaceuticals business of healthcare products provider Covidien, which specializes in products for diagnostic procedures and the treatment of pain and related conditions. In December 2011 Covidien announced plans to spin off the firm as a stand-alone company. The move is expected to be completed during mid-2013.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »